Reported 5 months ago
Goldman Sachs' chief US equity strategist David Kostin believes that the S&P 500 reaching above the 5,200 target he predicted indicates limited potential for further gains this year due to high stock valuations and low GDP projections. However, Goldman analysts remain optimistic about two stocks, Fulcrum Therapeutics and Marex Group, predicting potential returns of up to 108% and 61%, respectively. Fulcrum Therapeutics is a biopharmaceutical company focusing on genetically defined diseases, with promising drug candidates in advanced clinical stages, while Marex Group is a global financial services company that recently went public and shows strong growth potential in its various business segments.
Source: YAHOO